期刊
JOURNAL OF NUCLEAR MEDICINE
卷 62, 期 10, 页码 1380-1383出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.120.254482
关键词
F-18-FDG; PET/CT; bone marrow uptake; immunotherapy; melanoma
The study aimed to investigate the prognostic value of F-18-FDG PET/CT parameters in melanoma patients before starting anti-PD-1 therapy. Results showed that patients with a high BLR were associated with poorer progression-free and overall survival, potentially due to systemic inflammation leading to immunosuppression.
Our purpose was to investigate the prognostic value of F-18-FDG PET/CT parameters in melanoma patients before beginning therapy with antibodies to the programmed cell death 1 receptor (anti-PD-1). Methods: Imaging parameters including SUVmax, metabolic tumor volume, and the ratio of bone marrow to liver SUVmean (BLR) were measured from baseline PET/CT in 92 patients before the start of anti PD-1 therapy. The association with survival and imaging parameters combined with clinical factors was evaluated. Clinical and laboratory data were compared between the high-BLR group (<= median) and the low-BLR group (>median). Results: Multivariate analyses demonstrated that BLR was an independent prognostic factor for progression-free and overall survival (P = 0.017 and P = 0.011, respectively). The high-BLR group had higher white blood cell counts and neutrophil counts and a higher level of C-reactive protein than the low-BLR group (P < 0.05). Conclusion: Patients with a high BLR were associated with poor progression-free and overall survival, potentially explained by evidence of systemic inflammation known to be associated with immunosuppression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据